Running Oak Capital LLC Has $8.90 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Running Oak Capital LLC boosted its position in Boston Scientific Co. (NYSE:BSX) by 17.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 153,875 shares of the medical equipment provider’s stock after purchasing an additional 23,091 shares during the period. Running Oak Capital LLC’s holdings in Boston Scientific were worth $8,896,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of BSX. Bruce G. Allen Investments LLC acquired a new stake in Boston Scientific during the fourth quarter worth approximately $28,000. Venturi Wealth Management LLC lifted its holdings in shares of Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 215 shares during the period. Motco lifted its holdings in Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 372 shares during the period. Cetera Trust Company N.A bought a new stake in Boston Scientific in the fourth quarter valued at $43,000. Finally, Asset Dedication LLC increased its position in shares of Boston Scientific by 42.6% during the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 235 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Boston Scientific stock traded down $0.18 during trading on Thursday, reaching $72.03. The company had a trading volume of 6,489,001 shares, compared to its average volume of 6,639,147. The firm’s 50-day simple moving average is $68.20 and its 200 day simple moving average is $61.03. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The firm has a market capitalization of $108.05 billion, a PE ratio of 60.68, a price-to-earnings-growth ratio of 2.47 and a beta of 0.77. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. The company had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same quarter in the previous year, the company posted $0.45 EPS. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent research reports. Robert W. Baird upped their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Oppenheimer increased their price target on shares of Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a report on Thursday, February 1st. Barclays increased their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Evercore ISI increased their target price on shares of Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Finally, StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.09.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the sale, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,797 shares of company stock valued at $4,138,090. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.